Articles related to PROSTATE CANCER

In a significant shift, a new phase 3 trial suggests reconsidering adjuvant radiotherapy after radical prostatectomy, as many patients may not require it long-term, potentially reducing morbidity risks.

Prostate cancer survival rates have improved, but the incidence is rising, particularly for advanced cases. Addressing disparities in care is crucial.

The management of low-risk prostate cancer has seen a significant shift over the last two decades, with active surveillance increasingly becoming the preferred approach. However, despite this progress, the overtreatment of low-risk disease remains a concern, underscoring the need for continued refinement in patient selection and monitoring strategies.

According to investigators, definitive local therapy for patients with cT4 prostate cancer may improve local control and survival outcomes.

The phase 3 trial showed that enzalutamide, when used as a monotherapy or in combination with leuprolide, resulted in superior metastasis-free survival rates for patients with high-risk biochemical recurrence of prostate cancer.

Stay informed about the latest debates in prostate cancer treatment. Understand the implications of using docetaxel in high-risk localized cases.